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270 New nebulisers and colistin-resistant Pseudomonas aeuginosa
(crPA) in patients with cystic ﬁbrosis (CF)
A. Hurlow, I. Clifton, K. Pollard, C. Etherington, M. Denton, S. Conway,
D. Peckham. Regional CF Unit, Leeds, United Kingdom
Introduction: New nebulisers are associated with quicker treatment and possibly
improve concordance. Sputum microbiology monitoring suggested an increased
incidence of crPA from patients prescribed colistin delivered via the iNeb. The
study aimed to determine risk factors for the isolation of crPA in adults with CF
prescribed colistin delivered via the iNeb.
Methods: The study was undertaken at the Leeds Regional CF Unit. Between June
2005 and June 2006 all patients using an iNeb were identiﬁed and their hospital
records reviewed. The following data were recorded; demographics, antibiotic
courses after starting the iNeb, and isolates of crPA during and in the 5 years
prior to iNeb use.
Results: 71 patients were identiﬁed during the study period, 8 (11.2%) of whom
grew a crPA after commencing nebulised colistin via the iNeb. There was no
signiﬁcant difference between the patients with and without crPA in the sputum
after starting using the iNeb in terms of age, gender, number of courses of IV
antibiotics or courses of IV colistin. Patients who grew a crPA post-iNeb were
signiﬁcantly more likely to have had a positive sputum culture for crPA pre-iNeb
(9.5% v 87.5%) (Fisher Exact test P< 0.005).
Conclusion: crPA isolates are rare in patients with CF. Colistin resistance is due to
structural modiﬁcations of the outer cell membrane. Patients who have grown crPA
prior to starting nebulising colistin via an iNeb are at increased risk of doing so
afterwards. Further studies are required to determine if this relates to issues of drug
distribution and/or concordance. Patients who have had positive sputum culture for
crPA should be closely monitored after commencement of colistin delivered via the
iNeb for recurrence of isolates of crPA.
271* Achieving sustained compliance with nebulised therapies in a
paediatric CF population
P. McCormack, A. McDonald, K.W. Southern, P.S. McNamara. Regional CF Centre,
Royal Liverpool Children’s Hospital, Liverpool, United Kingdom
Adaptive aerosol delivery (AAD) devices have been introduced into our clinic for
inhaled antibiotic (primarily colistin) and DNase treatments. They have been well
received and with correct breathing technique signiﬁcantly reduce treatment times.
Using a software package provided by one of the manufacturers, compliance with
morning and evening treatments was calculated after a variable run-in period and at
regular 3 monthly intervals over a year. Feedback on compliance data and breathing
technique were given by a physiotherapist to both parents and child at a clinic
appointment immediately after the run-in period and at subsequent routine clinic visits.
Since March 2005, 69 patients have been established on an AAD device (age range
2−17 years) for variable periods of time (3−18 months) depending on indication.
Median treatment times range between 2−8 minutes. Compliance data from a random
selection of patients (11/69) have so far been analysed (see Table). These show that
treatment compliance through the device was good, that it increased following the ﬁrst
feedback session at the end of the run-in period (p< 0.05) and that it was maintained.
Evening compliance was signiﬁcantly better than morning compliance (p< 0.05).
These data suggest that the in-device data logger provides a valuable resource for the
clinic physiotherapist to work with patients at achieving sustainable aerosolised therapy.
Morning and evening compliance following the start of nebulised therapy
Mean (SD) morning compliance (%) Mean (SD) evening compliance (%)
Run-in period (n = 11) 47 (38) 65 (33)
3 months (n = 11) 68 (24) 89 (14)
6 months (n = 11) 66 (32) 86 (15)
9 months (n = 9) 63 (34) 79 (31)
272 Satisfaction survey concerning vibrating mesh-nebulizer in
CF patients
G. Reychler1, P. Lebecque1, C. Knoop2, C. Opdekamp2. 1CF Center, Cliniques
Universitaires Saint-Luc, Brussels, Belgium; 2CF Center, Hoˆpital universitaire
Erasme, Brussels, Belgium
Vibrating-mesh nebulizers are more and more frequently used in CF patients.
Patients’ satisfaction with their nebulizer plays a key role in adherence to treatment
and, thus, is of prime importance in the evaluation of new devices.
Study objective: The aim of this study was to assess patients’ satisfaction with
the E-Flow nebulizer (Pari, Germany) by a questionnaire and to compare it with
classical devices.
Method: A questionnaire was developed from elements contributing to patients’
adherence with nebulization. A group of patients using E-Flow were asked to
compare their satisfaction concerning E-Flow (Group 1) with their old nebulizer
(Group 2). The same questionnaire was submitted to a control group of patients
who had never used an E-Flow nebulizer (Group 3). Their level of satisfaction was
rated using a 1 (unsatisﬁed) to 10 (completely satisﬁed) Likert scale.
Results: 46 patients were included in Groups 1 and 2 and 33 patients in Group 3
respectively. Group 1 notiﬁed that all items were more satisfying (between 8.1 and
9.7) compared with Group 2 (between 4.5 and 8.3). In Group 3, satisfaction varied
between 5.1 and 8.3. A signiﬁcant difference was found for ease of use (p = 0.002)
and of maintenance (p = 0.002), duration of the nebulization (p< 0.0001), portability
of the device (p< 0.0001), noise (p< 0.0001) and global satisfaction (p< 0.0001)
between group 1 and group 3 but no difference was found for subjective therapeutic
efﬁcacy, comfort related to nebulization nor adherence.
Conclusion: The results preliminary of our survey show an improvement of global
and individual satisfaction for speciﬁc items when using the E-Flow nebulizer. This
has to be conﬁmed in larger studies.
273 Educational leaﬂets to improve use of volume space device in
children with CF
M. Sallort, D. Fezaa, M. Clairicia, S. Vrielynck, G. Lenoir, I. Sermet-Gaudelus.
CRCM, Hoˆpital Necker, Paris, France
Administration of inhaled bronchodilators or steroids is a major component of
treatment in CF. Using a volume space device improves drug delivery. We conducted
an observational study in 50 children with CF less than 15 years old and observed
that most of them had a lack of breath coordination. Moreover, cleaning and
maintenance were not appropriate.
We therefore undertook an educational program aiming at improving the use of this
device. We implemented simple leaﬂets on followings: beneﬁt of using this device;
respective characteristics of the different models; appropriate technique; cleaning
and maintenance; questions and answers, practical examples. These documents were
explained by the physiotherapist and the nurse during routine clinics. An evaluation
study in the children and family who took part to this educational program has
evidenced improvement of the technique.
Despite apparent simplicity, holding chamber devices are often misused by the
patients. Regular assessment of the technique and education if necessary must be
undertaken.
